Table I.
Immunohistochemical analysis of 16 cases of DLBCL (de novo) and three cases of Richter transformation.
| Case | Immunohistochemistry |
Morphology | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CD20 | CD5 | MIB1* | BCL2 | CD10 | MUM1 | BCL6 | Cyclin D1* | ||
| De novo | |||||||||
| 1 | + | − | 50 | + | − | + | + | 20 | IB |
| 2 | + | − | 40 | + | − | +/− | − | 15 | CB |
| 3 | + | − | 45 | − | − | + | + | 15 | CB |
| 4 | + | − | 70 | + | − | + | + | 10 | CB |
| 5 | + | − | 80 | + | − | + | + | 20 | CB |
| 6 | + | − | 70 | − | − | + | + | 20 | CB |
| 7 | + | − | 70 | − | − | − | + | 20 | CB |
| 8 | + | − | 75 | − | − | − | + | 20 | CB |
| 9 | + | − | 40 | + | − | + | + | 20 | CB |
| 10 | + | − | 80 | 7 | − | + | + | 30 | CB |
| 11† | + | − | 60 | +/− | − | − | + | 30 | CB |
| 12† | + | − | 70 | NA | − | + | −/+ | 20 | CB |
| 13† | + | − | 60 | NA | − | + | + | 20 | T/HRLBCL |
| 14† | + | − | 80 | NA | − | + | + | 10 | CB |
| 15† | + | − | 90 | + | − | + | + | 20 | CB |
| 16† | + | Weak | 50 | + | − | + | −/+ | 20 | CB |
| RT | |||||||||
| 17 | − | − | 90 | NA | − | + | + | 80 | CB |
| 18† | + | − | 70 | + | − | + | + | 70 | CB |
| 19 | + | − | 70 | + | − | + | + | 20 | CB |
*
For cyclin D1 staining and proliferation fraction (MIB1) the percentage of positive cells is given.
†
Cases 11–16 and 18 were not part of the original cohort of 66 cases, but independently identified.
DLBCL, diffuse large B-cell lymphoma; RT, Richter transformation; NA, not available; IB, immunoblastic; CB, centroblastic; T/HRLBCL:,T-cell/histiocyte-rich large B-cell lymphoma.